Principal Investigator: Professor Dame Lesley Fallowfield

Lead Researchers: Dr Valerie Jenkins, Dr Susan Catt

Statistician: Dr Ivonne Solis-Trapala

Funded by: Boehringer Ingelheim GMBH

Progression Free Survival (PFS) is commonly used as an endpoint in clinical trials of novel cancer therapies. The aim of this study is to find out what this means for patients. What they understand about and expect from these treatments and if the benefits from the treatment controlling the cancer make it worth any side effects they could or do experience.  

^ Top